ClinicalTrials.gg
Active, not recruitingNCT05695027Updated Jul 15, 2026

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

A Phase 2/3 interventional study of Dietary supplements - Nicotinamide and Pyruvate and Placebo in Primary Open Angle Glaucoma, sponsored by Columbia University. Active, not recruiting at 3 sites in United States. Open to participants aged 35 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Columbia University · Phase 2/3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Planned enrollment
53rd of 279
250 · median 84
Started
2023
with 13 others
Phase 2/3
5 of 348
none open now
Primary completion
2027-08
later than 40 of 66 live
Registered
283rd of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 53rd largest by planned enrollment of the 279 interventional ones that give a count, is one of 14 that started in 2023, is one of 5 in phase 2/3, reaches primary completion later than 40 of the 66 other live ones, and was the 283rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.

A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).

Read the detailed description

Glaucoma is the leading cause of irreversible blindness worldwide. The most important test to detect progression is visual field testing or standard automated perimetry (SAP). The natural course of glaucoma includes a decline in visual function that matches optic nerve structural changes over time.

Both in clinical practice and in clinical trials, individuals undergo visual field testing at regular intervals in order to define whether progressive changes have occurred as well as the rapidity of change. Visual field results are highly variable within and between sessions, partly due to its subjective nature, which ultimately depends upon the test reliability, individuals' level of experience with the test, variability due to disease severity, and, importantly, the level of individual attentiveness during the test. Therefore, numerous attempts have been made to try to optimize individuals' performance during the test. Some of the approaches reported to date are listening to classical music mitigating background noise and use of nutritional supplements.

Recent studies have suggested that over-the-counter medications such as nicotinamide (vitamin B3) and pyruvate can also improve the performance during this test. The investigators are doing this research study to find out if taking nutritional supplements (vitamin B3 and pyruvate) available over- the-counter can help slow the rate of glaucomatous visual field progression compared to placebo.

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

Keywords

  • nutritional supplement
  • nicotinamide
  • pyruvate
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide for participation in the study.
  2. Between 35 and 85 years of age.
  3. Only one eligible eye per patient will be enrolled. If both eyes qualify, study eye will be elected based on the following characteristics (in order of most to least important): 1) disc hemorrhage, 2) higher intraocular pressure (IOP), 3) without previous filtering surgery, 4) better visual acuity. If both eyes meet these four criteria equally, then the study eye will be determined by random assignment.
  4. Have a confirmed diagnosis of primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma.
  5. If there is a prior reliable 24-2, the MD should be better than -20dB.
  6. Able to perform reliable visual field testing with 24-2 Swedish Interactive Threshold Algorithm (SITA)-Standard SAP (defined as false positive rates \<15%, false negative rates \<30%) at the most recent office visit.
  7. Have best corrected visual acuity better than or equal to 20/40 in the study eye.
  8. Have an IOP (treated or untreated) ≥ 14 mmHg and within 24 months of the baseline visit and one instance of historical IOP ≥ 16 mmHg by patient report or chart.

Exclusion criteria

Exclusion Criteria

  1. Glaucoma or cataract surgery anticipated in the next 18 months.
  2. Have a diagnosis of significant cataract or media opacity affecting the visual field test or imaging studies.
  3. Have a diagnosis of dementia, Alzheimer's, or other neurological disease.
  4. Have an inability to take or intolerance to nicotinamide and/or pyruvate.
  5. Have undergone incisional glaucoma surgery (trabeculectomy, glaucoma drainage implant, or Xen Gel Stent) within the last 12 months. Phacoemulsification ± canalicular micro-invasive glaucoma surgery (MIGS) is acceptable if performed ≥ 4 months prior to study entry.
  6. Prior complicated cataract surgery (e.g., vitrectomy, etc)
  7. Have a functioning trabeculectomy, glaucoma drainage implant, or Xen Gel Stent (defined as being on 0-1 glaucoma medications). If these surgeries have failed and the patient is on ≥ 2 classes of glaucoma medication and meets all other entry criteria, he/she is eligible).
  8. Retinal pathology that significantly affects visual acuity (worse than 20/40) or visual field.
  9. Refractive disorders and disorders other than glaucoma known to affect the visual field (VF) and macular optical coherence tomography (OCT) imaging (e.g., epiretinal membrane, cystoid macular edema, pathologic myopia, cylinder > 3 diopters, prior history of pars plana vitrectomy with internal limiting membrane peel).
  10. IOP at screening or baseline visit ≥ 25 mmHg.
  11. Have a known history of liver disease.
  12. Are pregnant or are planning to become pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Nicotinamide and Pyruvate

    The N\&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).

    Drug: Dietary supplements - Nicotinamide and Pyruvate

  • Placebo comparator
    Placebo

    The placebo group will receive placebo for 87 weeks (20 months).

    Drug: Placebo

Interventions

  • DrugDietary supplements - Nicotinamide and Pyruvate

    Nutritional supplements

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in visual field results based on pointwise and global metrics

    The primary outcome in this study are changes in visual field results based on pointwise and global metrics between intervention and placebo groups.

    Time frame: 87 weeks

  2. Change in retinal nerve fiber and ganglion cell layer thickness

    The primary outcome in this study are changes in retinal nerve fiber and ganglion cell layer thickness as assessed by optical coherence tomography testing between intervention and placebo groups.

    Time frame: 87 weeks

07

Study locations

3 sites
  • Stanford University Department of Ophthalmology
    Palo Alto, California 94303, United States
  • ColumbiaDoctors Ophthalmology - 880 Third Avenue
    New York, New York 10022, United States
  • Columbia University Irving Medical Center - 622 W 168th St
    New York, New York 10032, United States
08

References and documents

Publications

  • Liebmann JM, Cioffi GA. Nicking Glaucoma with Nicotinamide? N Engl J Med. 2017 May 25;376(21):2079-2081. doi: 10.1056/NEJMcibr1702486. No abstract available. PubMed 28538117 ↗
  • De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2022 Jan 1;140(1):11-18. doi: 10.1001/jamaophthalmol.2021.4576. PubMed 34792559 ↗
  • Williams PA, Harder JM, Foxworth NE, Cardozo BH, Cochran KE, John SWM. Nicotinamide and WLDS Act Together to Prevent Neurodegeneration in Glaucoma. Front Neurosci. 2017 Apr 25;11:232. doi: 10.3389/fnins.2017.00232. eCollection 2017. PubMed 28487632 ↗
  • Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017 Feb 17;355(6326):756-760. doi: 10.1126/science.aal0092. PubMed 28209901 ↗
  • Shukla AG, Cioffi GA, Liebmann JM. Drug-Induced Liver Injury During a Glaucoma Neuroprotection Clinical Trial. J Glaucoma. 2024 Aug 1;33(8):e58-e59. doi: 10.1097/IJG.0000000000002394. Epub 2024 Mar 28. PubMed 38536128 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Aug 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Jan 23, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05695027
Collaborators
Stanford University
Responsible party
Aakriti G. Shukla (Principal Investigator, Columbia University) — Principal investigator
First posted
Jan 23, 2023
Start date
Mar 14, 2023
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Aakriti G. Shukla, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion